Magnum Ice Cream Co has become one of Europe’s most heavily shorted stocks, as hedge funds position against the company on concerns over weakening demand, margin pressure and shifting consumer behaviour, according to a report by Bloomberg.
The company has quickly attracted significant short interest following its 2025 spin-off from Unilever Plc, with bearish investors increasingly targeting the stock.
Data from S&P Global Market Intelligence shows that shares on loan — a common indicator of short positioning — have risen to around 19% of the company’s free float as of mid-April, more than doubling over the past month. This places Magnum among the most shorted constituents of the Stoxx 600 Index.
The company’s shares have struggled to gain traction since listing, falling roughly 14% so far this year and trading below their IPO price.
A key concern among investors is the potential impact of rising use of GLP-1 weight-loss drugs, which may dampen demand for indulgent, high-calorie products such as ice cream. Analysts have flagged this as a structural headwind for the sector.
Hedge funds have been actively building positions. Walleye Capital LLC recently increased its net short exposure, while firms including Marshall Wace LLP and Ilex Capital Partners (UK) LLP have also taken bearish views on the stock.
Sell-side sentiment has also softened. An analyst at BNP Paribas SA downgraded the shares, pointing to evolving consumer preferences and the potential impact of GLP-1 adoption, alongside inflationary pressures linked to geopolitical tensions.
Rising input costs are another area of concern. Analysts warn that higher energy prices could weigh on profitability, while broader macro uncertainty — including the potential impact of the Iran conflict on consumer confidence — may further pressure demand for discretionary food products.
